CTOs on the Move

The Friedman Marketing Group

www.tfmgcom.com

 
The Friedman Marketing Group is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tfmgcom.com
  • 8985 Vanns Tavern Rd
    Gainesville, GA USA 30506
  • Phone: 770.888.5260

Executives

Name Title Contact Details

Similar Companies

Los Ninos Services

Los Ninos Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Assurance Company Of Mississippi

Medical Assurance Company Of Mississippi is a Ridgeland, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AKH

AKH is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

William F Ryan Community Health Ctr

William F Ryan Community Health Ctr is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New York, NY. To find more information about William F Ryan Community Health Ctr, please visit www.ryancenter.org

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.